CellSource Co

CellSource Co SG&A Expenses

The Selling, General & Administrative Expenses of CellSource Co (4880.T) as of Oct 28, 2026 is 290.75 M JPY. In the previous year, Selling, General & Administrative Expenses was 302.43 M JPY — a change of -3.86% (lower).

SG&A Expenses

290.75 MJPY

YoY

-3.86%

Last updated:

Selling, General & Administrative Expenses of CellSource Co is 2024 290.75 M JPY. Selling, General & Administrative Expenses of CellSource Co was 2023 302.43 M JPY. It decreases by -3.86% lower compared to the previous year.

The CellSource Co SG&A Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SG&A Expenses
Date
SG&A Expenses
Jan 1, 2017
77.63 M JPY
Jan 1, 2018
247.16 M JPY
Jan 1, 2019
145.47 M JPY
Jan 1, 2020
169.86 M JPY
Jan 1, 2021
204.85 M JPY
Jan 1, 2022
324.05 M JPY
Jan 1, 2023
302.43 M JPY
Jan 1, 2024
290.75 M JPY
The CellSource Co SG&A Expenses history
YEARSG&A ExpensesYoY
290.75 MJPY-3.86%
302.43 MJPY-6.67%
324.05 MJPY+58.19%
204.85 MJPY+20.60%
169.86 MJPY+16.77%
145.47 MJPY-41.14%
247.16 MJPY+218.39%
77.63 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Selling, General & Administrative Expenses of CellSource Co is 290.75 M JPY in 2024.

Selling, General & Administrative Expenses of CellSource Co changed from 302.43 M JPY to 290.75 M JPY, representing a -3.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Selling, General & Administrative Expenses CellSource Co since 2006 – with annual values, charts, and detailed analysis.

SG&A expenses include all non-production costs such as salaries, marketing, rent, and administrative overhead. They are a key component of operating expenses.

Selling, General & Administrative Expenses's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Selling, General & Administrative Expenses's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CellSource Co

All Key Metrics — CellSource Co